Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Page 1
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study.
Daines CL, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, Quon BS, Ringshausen FC, Rowe SM, Selvadurai H, Taylor-Cousar JL, Withers NJ, Ahluwalia N, Moskowitz SM, Prieto-Centurion V, Tan YV, Tian S, Weinstock T, Xuan F, Zhang Y, Ramsey B, Griese M; VX17-445-105 Study Group. Daines CL, et al. Among authors: tullis e. Eur Respir J. 2023 Dec 7;62(6):2202029. doi: 10.1183/13993003.02029-2022. Print 2023 Dec. Eur Respir J. 2023. PMID: 37945033 Free PMC article. Clinical Trial.
BACKGROUND: In two pivotal phase 3 trials, up to 24 weeks of treatment with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was efficacious and safe in patients with cystic fibrosis (CF) 12 years of age who have at least one F508del allele. The aim of this study is to assess long- …
BACKGROUND: In two pivotal phase 3 trials, up to 24 weeks of treatment with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was efficacious a …
Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass.
Mouzaki M, Dupuis A, Avolio J, Griffin K, Ratjen F, Tullis E, Gonska T. Mouzaki M, et al. Among authors: tullis e. Front Pharmacol. 2023 Jul 13;14:1157459. doi: 10.3389/fphar.2023.1157459. eCollection 2023. Front Pharmacol. 2023. PMID: 37521467 Free PMC article.
Background: Ivacaftor, the first CFTR modulator drug, leads to significant long-term improvement in lung function and weight gain. The mechanism as well as the long-term impact of ivacaftor on weight, resting energy expenditure (REE) and body composition remains to …
Background: Ivacaftor, the first CFTR modulator drug, leads to significant long-term improvement in lung function and weight gain. Th …
Lung transplantation for cystic fibrosis.
Yeung JC, Machuca TN, Chaparro C, Cypel M, Stephenson AL, Solomon M, Saito T, Binnie M, Chow CW, Grasemann H, Pierre AF, Yasufuku K, de Perrot M, Donahoe LL, Tikkanen J, Martinu T, Waddell TK, Tullis E, Singer LG, Keshavjee S. Yeung JC, et al. Among authors: tullis e. J Heart Lung Transplant. 2020 Jun;39(6):553-560. doi: 10.1016/j.healun.2020.02.010. Epub 2020 Feb 20. J Heart Lung Transplant. 2020. PMID: 32147452
CONCLUSIONS: Lung transplantation for CF provides excellent short- and long-term outcomes. These results strongly support lung transplantation as the standard of care for patients with CF having advanced lung disease....
CONCLUSIONS: Lung transplantation for CF provides excellent short- and long-term outcomes. These results strongly support lung transp …
Long-term effect of CFTR modulator therapy on airway nitric oxide.
Grasemann H, Klingel M, Avolio J, Prentice C, Gonska T, Tullis E, Ratjen F. Grasemann H, et al. Among authors: tullis e. Eur Respir J. 2020 Jan 9;55(1):1901113. doi: 10.1183/13993003.01113-2019. Print 2020 Jan. Eur Respir J. 2020. PMID: 31601715 Free article. No abstract available.
Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis.
Stanojevic S, McDonald A, Waters V, MacDonald S, Horton E, Tullis E, Ratjen F. Stanojevic S, et al. Among authors: tullis e. Thorax. 2017 Apr;72(4):327-332. doi: 10.1136/thoraxjnl-2016-208450. Epub 2016 Aug 18. Thorax. 2017. PMID: 27539619
Michael's Hospital from 2009 to 2014. We evaluated the effect of oPEx on short-term clinical outcomes as the proportion of oPEx events in which 100% or 90% of baseline FEV(1)% predicted was recovered at the end of treatment. ...When the cumulative effect of oPExs on lung f …
Michael's Hospital from 2009 to 2014. We evaluated the effect of oPEx on short-term clinical outcomes as the proportion of oPEx event …
Longitudinal relationship between physical activity and lung health in patients with cystic fibrosis.
Schneiderman JE, Wilkes DL, Atenafu EG, Nguyen T, Wells GD, Alarie N, Tullis E, Lands LC, Coates AL, Corey M, Ratjen F. Schneiderman JE, et al. Among authors: tullis e. Eur Respir J. 2014 Mar;43(3):817-23. doi: 10.1183/09031936.00055513. Epub 2013 Oct 31. Eur Respir J. 2014. PMID: 24176992 Free article.
Exercise is beneficial for patients with cystic fibrosis (CF) but long-term effects of physical activity on lung function evolution are unknown. ...
Exercise is beneficial for patients with cystic fibrosis (CF) but long-term effects of physical activity on lung function evolution a …
A lifecourse approach to health development: implications for the maternal and child health research agenda.
Russ SA, Larson K, Tullis E, Halfon N. Russ SA, et al. Among authors: tullis e. Matern Child Health J. 2014 Feb;18(2):497-510. doi: 10.1007/s10995-013-1284-z. Matern Child Health J. 2014. PMID: 23955383
Addressing knowledge gaps will require an emphasis on longitudinal rather than cross-sectional studies, long-term (lifetime) rather than short-term perspectives, datasets that include socio-demographic, biologic and genetic data on the same subjects rather than disc …
Addressing knowledge gaps will require an emphasis on longitudinal rather than cross-sectional studies, long-term (lifetime) rather t …
Long term effects of denufosol tetrasodium in patients with cystic fibrosis.
Ratjen F, Durham T, Navratil T, Schaberg A, Accurso FJ, Wainwright C, Barnes M, Moss RB; TIGER-2 Study Investigator Group. Ratjen F, et al. J Cyst Fibros. 2012 Dec;11(6):539-49. doi: 10.1016/j.jcf.2012.05.003. Epub 2012 Jun 8. J Cyst Fibros. 2012. PMID: 22682898 Free article. Clinical Trial.
Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis.
Waters V, Stanojevic S, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Waters V, et al. Among authors: tullis e. Eur Respir J. 2012 Jul;40(1):61-6. doi: 10.1183/09031936.00159111. Epub 2011 Dec 1. Eur Respir J. 2012. PMID: 22135280 Free article.
It is unknown what proportion of long-term lung function decline in cystic fibrosis (CF) is explained by pulmonary exacerbations. ...
It is unknown what proportion of long-term lung function decline in cystic fibrosis (CF) is explained by pulmonary exacerbations. ...
Survival of Burkholderia cepacia sepsis following lung transplantation in recipients with cystic fibrosis.
Nash EF, Coonar A, Kremer R, Tullis E, Hutcheon M, Singer LG, Keshavjee S, Chaparro C. Nash EF, et al. Among authors: tullis e. Transpl Infect Dis. 2010 Dec;12(6):551-4. doi: 10.1111/j.1399-3062.2010.00525.x. Transpl Infect Dis. 2010. PMID: 20553438 Review.
B. cepacia complex (BCC) sepsis is one of the defining criteria for cepacia syndrome, an almost universally fatal necrotizing pneumonic illness. We report 2 CF patients who were long-term survivors of B. cenocepacia sepsis after lung transplantation. The aim of this report …
B. cepacia complex (BCC) sepsis is one of the defining criteria for cepacia syndrome, an almost universally fatal necrotizing pneumonic illn …
14 results